FTY720, a Novel Immunosuppressant, Induces Sequestration of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing in Rats. II. FTY720 Prolongs Skin Allograft Survival by Decreasing T Cell Infiltration into Grafts But Not Cytokine Production In Vivo
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
FTY720, a novel immunosuppressant, prolonged the survival of WKAH skin allografts transplanted into MHC-incompatible F344 rats. In this allograft model, the median survival time of the control group was 7 days, whereas those of the groups given FTY720 orally at 0.1 mg/kg and cyclosporin A (CsA) at 10 mg/kg were 10.5 and 11 days, respectively. In contrast, FTY720 (0.1 mg/kg) combined with CsA (10 mg/kg) synergistically prolonged allograft survival with a median survival time exceeding 70 days. To elucidate the mechanisms of this remarkable synergistic effect, mRNA expressions of IL-2 and IFN-γ and that of CD3 (δ-chain), which reflects T cell infiltration, in allografts were temporally analyzed using a semiquantitative PCR method. In WKAH skin allografts, mRNA levels of IL-2, IFN-γ, and CD3 were increased as compared with isograft controls, peaking on days 4 to 5. CsA (10 mg/kg) significantly inhibited elevations of IL-2 and IFN-γ mRNA, while slightly inhibiting that of CD3 mRNA in allografts. On the contrary, FTY720 (0.1 mg/kg) markedly inhibited the elevation of CD3 mRNA, while slightly inhibiting those of IL-2 and IFN-γ mRNA. FTY720 (0.1 mg/kg) combined with CsA (10 mg/kg) almost completely suppressed the intragraft expressions of mRNA for IL-2, IFN-γ, and CD3. Immunohistochemical staining and flow cytometric analysis also confirmed that FTY720 decreased T cell infiltration into allografts. From these results, the synergistic effect of FTY720 combined with CsA on prolongation of allograft survival is presumably based on the respective inhibitions of T cell infiltration and cytokine production in grafts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Chiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., & Hoshino, Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.5037 · Cited by 596
Self-citationInduction of Interleukin 2 Messenger RNA Inhibited by Cyclosporin A
Elliott, J. F., Lin, Y., Mizel, S. B., Bleackley, R. C., Harnish, D. G., & Paetkau, V. (1984) · Science · doi:10.1126/science.6334364 · Cited by 395
Effects of cyclosporine A on T cell development and clonal deletion
Jenkins, M., Schwartz, R., & Pardoll, D. (1988) · Science · doi:10.1126/science.241.4873.1655 · Cited by 341
Adachi, K., Kohara, T., Nakao, N., Arita, M., Chiba, K., Mishina, T., Sasaki, S., & Fujita, T. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00127-f · Cited by 304
Self-citationSuzuki, S., Enosawa, S., Kakefuda, T., Shinomiya, T., Amari, M., Naoe, S., Hoshino, Y., & Chiba, K. (1996) · Transplantation · doi:10.1097/00007890-199601270-00006 · Cited by 283
Self-citationSiegling, A., Lehmann, M., Platzer, C., Emmrich, F., & Volk, H.-D. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90139-2 · Cited by 174
Potent Immunosuppressants, 2-Alkyl-2-aminopropane-1,3-diols
Fujita, T., Hirose, R., Yoneta, M., Sasaki, S., Inoue, K., Kiuchi, M., Hirase, S., Chiba, K., Sakamoto, H., & Arita, M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960391l · Cited by 133
Self-citationO'Connell, P. J., Pacheco‐Silva, Á., Nickerson, P. W., Muggia, R. A., Bastos, M. G., Kelley, V. R., & Strom, T. B. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.3.1093 · Cited by 131
Chiba, K., Hoshino, Y., Suzuki, T., Masubuchi, Y., Yanagawa, Y., Ohtsuki, M., Sasaki, S., & Fujita, T. (1996) · PubMed · Cited by 127
Self-citation
Cited by
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,504
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
“Early studies in animals showed that fingolimod synergized with calcineurin inhibitors , which inhibit the proliferation of T cells and prolong organ graft surviva”
BackgroundThe PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
Dammeijer, F., van Gulijk, M., Mulder, E. E., Lukkes, M., Klaase, L., van den Bosch, T., van Nimwegen, M., Lau, S. P., Latupeirissa, K., Schetters, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.001 · Cited by 695
The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors
Gräler, M. H., & Goetzl, E. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-0910fje · Cited by 539
Brinkmann, V., Cyster, J. G., & Hla, T. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00476.x · Cited by 478
Sphingosine 1-Phosphate Receptor Signaling
Rosen, H., Gonzalez-Cabrera, P. J., Sanna, M. G., & Brown, S. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.072407.103733 · Cited by 404
Sanchez, T., Estrada-Hernandez, T., Paik, J.-H., Wu, M.-T., Venkataraman, K., Brinkmann, V., Claffey, K., & Hla, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306896200 · Cited by 374
Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors
Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., & Seuwen, K. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.173 · Cited by 370
Pinschewer, D. D., Ochsenbein, A. F., Odermatt, B., Brinkmann, V., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5761 · Cited by 365
Chiba, K. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.002 · Cited by 321
Self-citationAmelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, X.-K. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045658 · Cited by 280
First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients
Budde, K., Schmouder, R. L., Brunkhorst, R., Nashan, B., Lu[Combining Diaeresis]cker, P. W., Mayer, T., Choudhury, S., Skerjanec, A., Kraus, G., & Neumayer, H. H. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341073 · Cited by 270
Sphingosine 1-phosphate and inflammation
Obinata, H., & Hla, T. (2019) · International Immunology · doi:10.1093/intimm/dxz037 · Cited by 268
Brinkmann, V., & Lynch, K. R. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00374-6 · Cited by 262
Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY720
Kharel, Y., Lee, S., Snyder, A. H., Sheasley-O'Neill, S. L., Morris, M. A., Setiady, Y., Zhu, R., Zigler, M. A., Burcin, T. L., Ley, K., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506293200 · Cited by 210
Daniel, C., Sartory, N., Zahn, N., Geisslinger, G., Radeke, H. H., & Stein, J. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2458 · Cited by 165
Copland, D. A., Liu, J., Schewitz-Bowers, L. P., Brinkmann, V., Anderson, K., Nicholson, L. B., & Dick, A. D. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.008 · Cited by 50
Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease
Raveney, B. J. E., Copland, D. A., Nicholson, L. B., & Dick, A. D. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.10.1390 · Cited by 39
Tsuji, T., Okuno, S., Kuroda, A., Hamazaki, J., Chikami, T., Sakurai, S., Yoshida, Y., Banno, R., Fujita, T., & Kohno, T. (2016) · Allergology International · doi:10.1016/j.alit.2015.10.009 · Cited by 8
Metadata
- Authors
- Yanagawa, Y., Sugahara, K., Kataoka, H., Kawaguchi, T., Masubuchi, Y., & Chiba, K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-06-01
- Volume
- 160
- Issue
- 11
- Pages
- 5493-5499
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1562769137
- Cited by
- 260
- References
- 16
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.